Amylyx announces FDA granted orphan drug designation for AMX0035 to treat Wolfram syndrome

This article was originally published here

“There is a critical unmet need for people living with Wolfram syndrome, a rare genetic disease in which many patients die prematurely with severe neurological disabilities,” said Wolfram

The post Amylyx announces FDA granted orphan drug designation for AMX0035 to treat Wolfram syndrome appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply